BGI and LIAA Sign MOU on Research, Education and Human Health
Publish Date: 2017-10-02

October 2, 2017, Latvia-- BGI and Investment and Development Agency of Latvia (LIAA) signed Memorandum of Understanding on science and technology cooperation, in order to accelerate local life science industry development and improve people’s health.

According to the agreements, Latvian government and BGI agree to discuss and explore a cooperative program that includes collaborations to advance research, educational opportunities and human health.

The Co-founder and President of BGI Jian Wang commented, “with its strengths on technology, research and industrial application, BGI is dedicated to benefit local community in aspects of scientific research, technology applications and clinical services”. 

The Executive Vice President of BGI Duncan Yu also addressed that the two sides have already discussed several cooperation interests, since the last time Raimonds Aleksejenko, the Latvian Economy Ministry's deputy state secretary, visited China National GeneBank in Shenzhen. And he would be willing to establish a trans-omics joint-lab through efforts of both sides for local life science development, referring to BGI’s former successful experiences of labs launching in China.

In addition, the Prime Minister of Latvia Maris Kucinskis expressed the faith in future cooperation with BGI, and he hoped that BGI could contribute to local scientific research and technology application development with its advanced gene technology and services, to accelerate economic development as well as improve people’s health for public good.


About LIAA

LIAA, as a direct administration institution subordinated to the Minister of Economics of the Republic of Latvia, is dedicated to promote business development by facilitating more foreign investment, in parallel increasing the competitiveness of Latvian entrepreneurs in both domestic and foreign markets.

About BGI

BGI, as a world-leading genomics organization, was founded in 1999 with the vision of using genomics to benefit mankind. BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI's own BGISEQ sequencing platform, economies of scale, and expert bioinformatics resources.